| Year |
Citation |
Score |
| 2023 |
Vergara S, Zhou X, Santiago U, Conway JF, Sluis-Cremer N, Calero G. Structures of kinetic intermediate states of HIV-1 reverse transcriptase DNA synthesis. Biorxiv : the Preprint Server For Biology. PMID 38187617 DOI: 10.1101/2023.12.18.572243 |
0.367 |
|
| 2023 |
Okpaise D, Sluis-Cremer N, Rappocciolo G, Rinaldo CR. Cholesterol Metabolism in Antigen-Presenting Cells and HIV-1 Trans-Infection of CD4 T Cells. Viruses. 15. PMID 38140588 DOI: 10.3390/v15122347 |
0.425 |
|
| 2023 |
Tuttle DJ, Castanha PMS, Nasser A, Wilkins MS, Galarza TG, Alaoui-El-Azher M, Cuff DE, Chhibbar P, Das J, Li Y, Barratt-Boyes SM, Mailliard RB, Sluis-Cremer N, Rinaldo CR, Marques ETA. SARS-CoV-2 mRNA vaccines induce greater complement activation and decreased viremia and Nef antibodies in men with HIV-1. The Journal of Infectious Diseases. PMID 38035792 DOI: 10.1093/infdis/jiad544 |
0.314 |
|
| 2023 |
Jennings J, Bracey H, Nguyen DT, Dasgupta R, Rivera AV, Sluis-Cremer N, Shi J, Aiken C. The HIV-1 capsid serves as a nanoscale reaction vessel for reverse transcription. Biorxiv : the Preprint Server For Biology. PMID 37986899 DOI: 10.1101/2023.11.08.566350 |
0.456 |
|
| 2023 |
Magnus M, Segarra L, Robinson B, Blankenship K, Corneli A, Ghebremichael M, Irvin N, McIntosh R, Favor KE, Jordan-Sciutto KL, Kimberly J, Sluis-Cremer N, Koethe JR, Newell A, Wood C, et al. Impact of a Multi-Institutional Initiative to Engage Students and Early-Stage Scholars From Underrepresented Racial and Ethnic Minority Groups in HIV Research: The Centers for AIDS Research Diversity, Equity, and Inclusion Pathway Initiative. Journal of Acquired Immune Deficiency Syndromes (1999). 94: S13-S20. PMID 37707843 DOI: 10.1097/QAI.0000000000003266 |
0.304 |
|
| 2023 |
Greenberg AE, Wutoh A, Bowleg L, Robinson B, Magnus M, Segarra L, Simon P, Wutoh A, Blankenship K, Burke M, Okeke NL, Corneli A, Hussen S, Holliday RC, Ciaranello A, ... ... Sluis-Cremer N, et al. Centers for AIDS Research (CFAR) Diversity, Equity, and Inclusion Pathway Initiative (CDEIPI): Developing Career Pathways for Early-Stage Scholars From Racial and Ethnic Groups Underrepresented in HIV Science and Medicine. Journal of Acquired Immune Deficiency Syndromes (1999). 94: S5-S12. PMID 37707842 DOI: 10.1097/QAI.0000000000003270 |
0.429 |
|
| 2023 |
Mansouri M, Rumrill S, Dawson S, Johnson A, Pinson JA, Gunzburg MJ, Latham CF, Barlow N, Mbogo GW, Ellenberg P, Headey SJ, Sluis-Cremer N, Tyssen D, Bauman JD, Ruiz FX, et al. Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach. Molecules (Basel, Switzerland). 28. PMID 37049868 DOI: 10.3390/molecules28073103 |
0.526 |
|
| 2023 |
Vargas B, Boslett J, Yates N, Sluis-Cremer N. Mechanism by Which PF-3758309, a Pan Isoform Inhibitor of p21-Activated Kinases, Blocks Reactivation of HIV-1 Latency. Biomolecules. 13. PMID 36671485 DOI: 10.3390/biom13010100 |
0.5 |
|
| 2021 |
Ilina TV, Brosenitsch T, Sluis-Cremer N, Ishima R. Retroviral RNase H: Structure, mechanism, and inhibition. The Enzymes. 50: 227-247. PMID 34861939 DOI: 10.1016/bs.enz.2021.07.007 |
0.385 |
|
| 2021 |
Sluis-Cremer N. Retroviral reverse transcriptase: Structure, function and inhibition. The Enzymes. 50: 179-194. PMID 34861936 DOI: 10.1016/bs.enz.2021.06.006 |
0.48 |
|
| 2021 |
Wei Y, Sluis-Cremer N. Mutations in the HIV-1 3'-Polypurine Tract and Integrase Strand-Transfer Inhibitor Resistance. Antimicrobial Agents and Chemotherapy. PMID 33722887 DOI: 10.1128/AAC.02432-20 |
0.573 |
|
| 2021 |
Gerberick A, DeLucia DC, Piazza P, Alaoui-El-Azher M, Rinaldo CR, Sluis-Cremer N, Rappocciolo G. B Lymphocytes, but Not Dendritic Cells, Efficiently HIV-1 Infect Naive CD4 T Cells: Implications for the Viral Reservoir. Mbio. 12. PMID 33688006 DOI: 10.1128/mBio.02998-20 |
0.46 |
|
| 2020 |
Sánchez-Murcia PA, de Castro S, García-Aparicio C, Jiménez MA, Corona A, Tramontano E, Sluis-Cremer N, Menéndez-Arias L, Velázquez S, Gago F, Camarasa MJ. Peptides Mimicking the β7/β8 Loop of HIV-1 Reverse Transcriptase p51 as "Hotspot-Targeted" Dimerization Inhibitors. Acs Medicinal Chemistry Letters. 11: 811-817. PMID 32435389 DOI: 10.1021/Acsmedchemlett.9B00623 |
0.48 |
|
| 2020 |
Kawai A, McElheny CL, Iovleva A, Kline EG, Sluis-Cremer N, Shields RK, Doi Y. Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in due to AmpC R2 loop deletion. Antimicrobial Agents and Chemotherapy. PMID 32284381 DOI: 10.1128/Aac.00198-20 |
0.346 |
|
| 2019 |
Rappocciolo G, Sluis-Cremer N, Rinaldo CR. Efficient HIV-1 Infection of CD4 T Cells Occurs in the Presence of Antiretroviral Therapy. Open Forum Infectious Diseases. 6: ofz253. PMID 31304185 DOI: 10.1093/Ofid/Ofz253 |
0.452 |
|
| 2019 |
Barnard JP, Huber KD, Sluis-Cremer N. NNRTI Hyper-Susceptibility and Resistance: Mutational Analysis of Residue 181 in HIV-1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy. PMID 31160281 DOI: 10.1128/Aac.00676-19 |
0.529 |
|
| 2019 |
Kristoff J, Palma ML, Garcia-Bates TM, Shen C, Sluis-Cremer N, Gupta P, Rinaldo CR, Mailliard RB. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1. Ebiomedicine. PMID 30952614 DOI: 10.1016/J.Ebiom.2019.03.077 |
0.517 |
|
| 2019 |
Zerbato JM, McMahon DK, Sobolewski MD, Mellors JW, Sluis-Cremer N. Naïve CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-Competent HIV-1. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30753360 DOI: 10.1093/Cid/Ciz108 |
0.492 |
|
| 2019 |
Tomich AD, Klontz EH, Deredge D, Barnard JP, McElheny CL, Eshbach ML, Weisz OA, Wintrode P, Doi Y, Sundberg EJ, Sluis-Cremer N. Small molecule inhibitor of FosA expands fosfomycin activity to multidrug-resistant Gram-negative pathogens. Antimicrobial Agents and Chemotherapy. PMID 30642934 DOI: 10.1128/Aac.01524-18 |
0.354 |
|
| 2018 |
Vargas B, Giacobbi NS, Sanyal A, Venkatachari NJ, Han F, Gupta P, Sluis-Cremer N. Inhibitors of Signaling Pathways that Block Reversal of HIV-1 Latency. Antimicrobial Agents and Chemotherapy. PMID 30455231 DOI: 10.1128/Aac.01744-18 |
0.554 |
|
| 2018 |
Sluis-Cremer N. Future of nonnucleoside reverse transcriptase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. PMID 29326232 DOI: 10.1073/Pnas.1720975115 |
0.602 |
|
| 2017 |
Ito R, Pacey MP, Mettus RT, Sluis-Cremer N, Doi Y. Origin of the plasmid-mediated fosfomycin resistance gene fosA3. The Journal of Antimicrobial Chemotherapy. PMID 29106538 DOI: 10.1093/Jac/Dkx389 |
0.304 |
|
| 2017 |
Guo Y, Tomich AD, McElheny CL, Cooper VS, Tait-Kamradt A, Wang M, Hu F, Rice LB, Sluis-Cremer N, Doi Y. High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium. Emerging Infectious Diseases. 23: 1902-1904. PMID 29048285 DOI: 10.3201/Eid2311.171130 |
0.36 |
|
| 2017 |
Ito R, Tomich AD, McElheny CL, Mettus R, Sluis-Cremer N, Doi Y. Inhibition of fosfomycin resistance protein FosA by phosphonoformate (foscarnet) in multidrug-resistant Gram-negative pathogens. Antimicrobial Agents and Chemotherapy. PMID 28993329 DOI: 10.1128/Aac.01424-17 |
0.343 |
|
| 2017 |
Klontz EH, Tomich AD, Günther S, Lemkul JA, Deredge D, Silverstein Z, Shaw JF, McElheny C, Doi Y, Wintrode P, MacKerell AD, Sluis-Cremer N, Sundberg EJ. Structure and dynamics of FosA-mediated fosfomycin resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and Chemotherapy. PMID 28874374 DOI: 10.1128/Aac.01572-17 |
0.36 |
|
| 2017 |
Ito R, Mustapha MM, Tomich AD, Callaghan JD, McElheny CL, Mettus RT, Shanks RMQ, Sluis-Cremer N, Doi Y. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. Mbio. 8. PMID 28851843 DOI: 10.1128/Mbio.00749-17 |
0.312 |
|
| 2017 |
Sanyal A, Mailliard RB, Rinaldo CR, Ratner D, Ding M, Chen Y, Zerbato JM, Giacobbi NS, Venkatachari NJ, Patterson BK, Chargin A, Sluis-Cremer N, Gupta P. Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4(+) T cells. Nature Medicine. PMID 28553933 DOI: 10.1038/Nm.4347 |
0.59 |
|
| 2017 |
Giacobbi NS, Sluis-Cremer N. In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine and MIV-150: NNRTI Microbicides in Clinical Development for the Prevention of HIV-1 Infection. Antimicrobial Agents and Chemotherapy. PMID 28507107 DOI: 10.1128/Aac.00277-17 |
0.537 |
|
| 2016 |
Zerbato JM, Tachedjian G, Sluis-Cremer N. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Virus Production from Latently Infected Resting CD4+ T Cells Following Latency Reversal. Antimicrobial Agents and Chemotherapy. PMID 27993846 DOI: 10.1128/Aac.01736-16 |
0.514 |
|
| 2016 |
Telwatte S, Brumme CJ, Hearps AC, Latham CF, Hayward JA, Sonza S, Sluis-Cremer N, Harrigan PR, Tachedjian G. Increasing Prevalence of Synonymous Mutations K65K and K66K in HIV-1 subtype B reverse transcriptase. Aids (London, England). PMID 27677159 DOI: 10.1097/Qad.0000000000001272 |
0.626 |
|
| 2016 |
Zerbato JM, Serrao E, Lenzi G, Kim B, Ambrose Z, Watkins SC, Engelman AN, Sluis-Cremer N. Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro. Journal of Virology. 90: 8059-73. PMID 27356901 DOI: 10.1128/Jvi.00553-16 |
0.509 |
|
| 2016 |
Guo Q, Tomich AD, McElheny CL, Cooper VS, Stoesser N, Wang M, Sluis-Cremer N, Doi Y. Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli. The Journal of Antimicrobial Chemotherapy. PMID 27261267 DOI: 10.1093/Jac/Dkw177 |
0.338 |
|
| 2016 |
Sluis-Cremer N. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells. Current Topics in Medicinal Chemistry. 16: 1191-7. PMID 26324046 DOI: 10.2174/1568026615666150901114138 |
0.53 |
|
| 2015 |
Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiology. 10: 1773-82. PMID 26517190 DOI: 10.2217/Fmb.15.106 |
0.616 |
|
| 2015 |
Venkatachari NJ, Zerbato JM, Jain S, Mancini AE, Chattopadhyay A, Sluis-Cremer N, Bar-Joseph Z, Ayyavoo V. Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch. Retrovirology. 12: 85. PMID 26438393 DOI: 10.1186/S12977-015-0211-3 |
0.558 |
|
| 2015 |
La J, Latham CF, Tinetti RN, Johnson A, Tyssen D, Huber KD, Sluis-Cremer N, Simpson JS, Headey SJ, Chalmers DK, Tachedjian G. Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. Proceedings of the National Academy of Sciences of the United States of America. 112: 6979-84. PMID 26038551 DOI: 10.1073/Pnas.1423900112 |
0.626 |
|
| 2015 |
Telwatte S, Hearps AC, Johnson A, Latham CF, Moore K, Agius P, Tachedjian M, Sonza S, Sluis-Cremer N, Harrigan PR, Tachedjian G. Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations. Nucleic Acids Research. 43: 3256-71. PMID 25765644 DOI: 10.1093/Nar/Gkv128 |
0.61 |
|
| 2014 |
Schauer GD, Huber KD, Leuba SH, Sluis-Cremer N. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. Nucleic Acids Research. 42: 11687-96. PMID 25232099 DOI: 10.1093/Nar/Gku819 |
0.49 |
|
| 2014 |
Sluis-Cremer N. The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses. 6: 2960-73. PMID 25089538 DOI: 10.3390/V6082960 |
0.576 |
|
| 2014 |
Sheen CW, Alptürk O, Sluis-Cremer N. Novel high-throughput screen identifies an HIV-1 reverse transcriptase inhibitor with a unique mechanism of action. The Biochemical Journal. 462: 425-32. PMID 24969820 DOI: 10.1042/Bj20140365 |
0.618 |
|
| 2014 |
Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, Mellors JW, Parkin NT, Harrigan PR. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. Antiviral Research. 107: 31-4. PMID 24746459 DOI: 10.1016/J.Antiviral.2014.04.001 |
0.514 |
|
| 2014 |
Doyon G, Sobolewski MD, Huber K, McMahon D, Mellors JW, Sluis-Cremer N. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1. Plos One. 9: e84964. PMID 24489654 DOI: 10.1371/Journal.Pone.0084964 |
0.602 |
|
| 2014 |
Sluis-Cremer N, Huber KD, Brumme CJ, Harrigan PR. Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine. Antimicrobial Agents and Chemotherapy. 58: 2430-3. PMID 24419343 DOI: 10.1128/Aac.02114-13 |
0.628 |
|
| 2014 |
Rothstein SN, Huber KD, Sluis-Cremer N, Little SR. In vitro characterization of a sustained-release formulation for enfuvirtide. Antimicrobial Agents and Chemotherapy. 58: 1797-9. PMID 24366751 DOI: 10.1128/Aac.02440-13 |
0.347 |
|
| 2014 |
Meteer JD, Schinazi RF, Mellors JW, Sluis-Cremer N. Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. Antiviral Research. 101: 62-7. PMID 24211331 DOI: 10.1016/J.Antiviral.2013.10.017 |
0.647 |
|
| 2013 |
Schauer G, Leuba S, Sluis-Cremer N. Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Biomolecules. 3: 889-904. PMID 24970195 DOI: 10.3390/biom3040889 |
0.513 |
|
| 2013 |
Herman BD, Sluis-Cremer N. Transient kinetic analyses of the ribonuclease H cleavage activity of HIV-1 reverse transcriptase in complex with efavirenz and/or a β-thujaplicinol analogue. The Biochemical Journal. 455: 179-84. PMID 23927736 DOI: 10.1042/Bj20130850 |
0.714 |
|
| 2013 |
Xu H, Franks T, Gibson G, Huber K, Rahm N, De Castillia CS, Luban J, Aiken C, Watkins S, Sluis-Cremer N, Ambrose Z. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology. 10: 70. PMID 23835323 DOI: 10.1186/1742-4690-10-70 |
0.513 |
|
| 2013 |
Brumme CJ, Huber KD, Dong W, Poon AF, Harrigan PR, Sluis-Cremer N. Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing. Journal of Virology. 87: 8805-7. PMID 23720723 DOI: 10.1128/Jvi.00335-13 |
0.628 |
|
| 2013 |
Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. Aids (London, England). 27: F7-F11. PMID 22739395 DOI: 10.1097/Qad.0B013E3283570620 |
0.575 |
|
| 2013 |
Schauer GD, Sluis-Cremer N, Leuba SH. Measurements of the Functional Dynamics of Wild Type and K103N HIV-1 Reverse Transcriptase Reveal the Mechanism of Efavirenz Resistance Biophysical Journal. 104: 420a-421a. DOI: 10.1016/J.Bpj.2012.11.2342 |
0.623 |
|
| 2012 |
Yap SH, Herman BD, Radzio J, Sluis-Cremer N, Tachedjian G. N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine. Journal of Acquired Immune Deficiency Syndromes (1999). 61: 153-7. PMID 22743599 DOI: 10.1097/Qai.0B013E3182657990 |
0.81 |
|
| 2012 |
Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 737-45. PMID 22618567 DOI: 10.1093/Cid/Cis501 |
0.551 |
|
| 2012 |
Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. Plos One. 7: e31558. PMID 22363673 DOI: 10.1371/Journal.Pone.0031558 |
0.643 |
|
| 2012 |
Herman BD, Schinazi RF, Zhang HW, Nettles JH, Stanton R, Detorio M, Obikhod A, Pradère U, Coats SJ, Mellors JW, Sluis-Cremer N. Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs. Nucleic Acids Research. 40: 381-90. PMID 21914723 DOI: 10.1093/Nar/Gkr756 |
0.808 |
|
| 2012 |
Schauer GD, Sluis-Cremer N, Leuba SH. Direct Measurement of HIV-1 Reverse Transcriptase Binding Kinetics, One Complex at a Time Biophysical Journal. 102: 484a. DOI: 10.1016/J.Bpj.2011.11.2651 |
0.509 |
|
| 2011 |
Radzio J, Sluis-Cremer N. Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase. Retrovirology. 8: 69. PMID 21859446 DOI: 10.1186/1742-4690-8-69 |
0.816 |
|
| 2011 |
Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF. Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. European Journal of Medicinal Chemistry. 46: 3832-44. PMID 21700368 DOI: 10.1016/J.Ejmech.2011.05.051 |
0.74 |
|
| 2011 |
Meteer JD, Koontz D, Asif G, Zhang HW, Detorio M, Solomon S, Coats SJ, Sluis-Cremer N, Schinazi RF, Mellors JW. The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 55: 3758-64. PMID 21646480 DOI: 10.1128/Aac.00414-11 |
0.658 |
|
| 2011 |
Roy V, Obikhod A, Zhang HW, Coats SJ, Herman BD, Sluis-Cremer N, Agrofoglio LA, Schinazi RF. Synthesis and anti-HIV evaluation of 3'-triazolo nucleosides. Nucleosides, Nucleotides & Nucleic Acids. 30: 264-70. PMID 21623540 DOI: 10.1080/15257770.2011.580291 |
0.783 |
|
| 2011 |
Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. The Journal of Biological Chemistry. 286: 22211-8. PMID 21531716 DOI: 10.1074/Jbc.M110.180224 |
0.598 |
|
| 2011 |
Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. Journal of Acquired Immune Deficiency Syndromes (1999). 56: 344-8. PMID 21350368 DOI: 10.1097/Qai.0B013E31820Cf029 |
0.516 |
|
| 2010 |
Ganguly S, Murugesan S, Prasanthi N, Alptürk O, Herman B, Sluis-Cremer N. Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs. Letters in Drug Design & Discovery. 7: 318-323. PMID 20535242 DOI: 10.2174/157018010791163424 |
0.807 |
|
| 2010 |
Ahn J, Byeon IJL, Dharmasena S, Huber K, Concel J, Gronenborn AM, Sluis-Cremer N. The RNA binding protein HuR does not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro Retrovirology. 7. PMID 20459669 DOI: 10.1186/1742-4690-7-40 |
0.536 |
|
| 2010 |
Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J. The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. The Journal of Biological Chemistry. 285: 12101-8. PMID 20164190 DOI: 10.1074/Jbc.M109.096529 |
0.803 |
|
| 2010 |
Radzio J, Yap SH, Tachedjian G, Sluis-Cremer N. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. Aids (London, England). 24: 659-67. PMID 20160634 DOI: 10.1097/Qad.0B013E328336781D |
0.791 |
|
| 2010 |
Sluis-Cremer N, Moore K, Radzio J, Sonza S, Tachedjian G. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. Aids (London, England). 24: 317-9. PMID 20010074 DOI: 10.1097/Qad.0B013E3283315697 |
0.808 |
|
| 2010 |
Zhang HW, Coats SJ, Bondada L, Amblard F, Detorio M, Asif G, Fromentin E, Solomon S, Obikhod A, Whitaker T, Sluis-Cremer N, Mellors JW, Schinazi RF. Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. Bioorganic & Medicinal Chemistry Letters. 20: 60-4. PMID 19948402 DOI: 10.1016/J.Bmcl.2009.11.031 |
0.548 |
|
| 2009 |
van Rooijen LB, Greengrass V, Morris LM, Plate MM, Gouillou M, Tachedjian G, Sluis-Cremer N, Hearps AC, Crowe SM. Effect of reverse transcriptase inhibitors and mutations on the low-cost Cavidi reverse transcriptase viral load assay. Journal of Acquired Immune Deficiency Syndromes (1999). 52: 527-9. PMID 19901621 DOI: 10.1097/Qai.0B013E3181B9E726 |
0.352 |
|
| 2009 |
Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW. Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. Antimicrobial Agents and Chemotherapy. 53: 3715-9. PMID 19596885 DOI: 10.1128/Aac.00392-09 |
0.596 |
|
| 2009 |
Ambrose Z, Herman BD, Sheen CW, Zelina S, Moore KL, Tachedjian G, Nissley DV, Sluis-Cremer N. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. Journal of Virology. 83: 3826-33. PMID 19193782 DOI: 10.1128/Jvi.01968-08 |
0.77 |
|
| 2008 |
Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry. 47: 14020-7. PMID 19067547 DOI: 10.1021/Bi8014778 |
0.555 |
|
| 2008 |
Harrigan PR, Sheen CW, Gill VS, Wynhoven B, Hudson E, Lima VD, Lecocq P, Aguirre R, Poon AF, Sluis-Cremer N. Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency. Aids (London, England). 22: 2501-8. PMID 19005273 DOI: 10.1097/Qad.0B013E328318F16C |
0.587 |
|
| 2008 |
Bonache MC, Quesada E, Sheen CW, Balzarini J, Sluis-Cremer N, Pérez-Pérez MJ, Camarasa MJ, San-Félix A. Novel N-3 substituted TSAO-T derivatives: synthesis and anti-HIV-evaluation. Nucleosides, Nucleotides & Nucleic Acids. 27: 351-67. PMID 18404570 DOI: 10.1080/15257770801943990 |
0.575 |
|
| 2008 |
Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Research. 134: 147-56. PMID 18372072 DOI: 10.1016/J.Virusres.2008.01.002 |
0.628 |
|
| 2008 |
Figueiredo A, Zelina S, Sluis-Cremer N, Tachedjian G. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Current Hiv Research. 6: 130-7. PMID 18336260 DOI: 10.2174/157016208783885065 |
0.585 |
|
| 2008 |
Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Molecular Pharmacology. 73: 601-6. PMID 18024510 DOI: 10.1124/Mol.107.038596 |
0.779 |
|
| 2008 |
Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrobial Agents and Chemotherapy. 52: 157-63. PMID 17967907 DOI: 10.1128/Aac.00904-07 |
0.808 |
|
| 2007 |
Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. Plos Medicine. 4: e335. PMID 18052601 DOI: 10.1371/Journal.Pmed.0040335 |
0.595 |
|
| 2007 |
Xia Q, Radzio J, Anderson KS, Sluis-Cremer N. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Science : a Publication of the Protein Society. 16: 1728-37. PMID 17656585 DOI: 10.1110/Ps.072829007 |
0.798 |
|
| 2007 |
Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. Aids (London, England). 21: 1405-14. PMID 17589186 DOI: 10.1097/Qad.0B013E3281Ac229B |
0.62 |
|
| 2007 |
Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. Journal of Virology. 81: 7852-9. PMID 17507476 DOI: 10.1128/Jvi.02203-06 |
0.547 |
|
| 2007 |
Nissley DV, Radzio J, Ambrose Z, Sheen CW, Hamamouch N, Moore KL, Tachedjian G, Sluis-Cremer N. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. The Biochemical Journal. 404: 151-7. PMID 17286555 DOI: 10.1042/Bj20061814 |
0.829 |
|
| 2007 |
Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 51: 48-53. PMID 17088490 DOI: 10.1128/Aac.00683-06 |
0.575 |
|
| 2007 |
Sluis-Cremer N. Molecular mechanisms of HIV-1 resistance to nucleoside and nucleotide reverse transcriptase inhibitors Future Hiv Therapy. 1: 191-201. DOI: 10.2217/17469600.1.2.191 |
0.644 |
|
| 2007 |
Amiji MM, Ananworanich J, Arrivé E, Sluis-Cremer N, Viganò A. Macrophage-targeted nanocarriers for anti-HIV therapy Therapy. 4: 715-719. DOI: 10.2217/14750708.4.6.715 |
0.387 |
|
| 2006 |
Figueiredo A, Moore KL, Mak J, Sluis-Cremer N, de Bethune MP, Tachedjian G. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. Plos Pathogens. 2: e119. PMID 17096588 DOI: 10.1371/Journal.Ppat.0020119 |
0.638 |
|
| 2006 |
Sluis-Cremer N, Hamamouch N, San Félix A, Velazquez S, Balzarini J, Camarasa MJ. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization. Journal of Medicinal Chemistry. 49: 4834-41. PMID 16884295 DOI: 10.1021/Jm0604575 |
0.556 |
|
| 2006 |
Srivastava S, Sluis-Cremer N, Tachedjian G. Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target Current Pharmaceutical Design. 12: 1879-1894. PMID 16724954 DOI: 10.2174/138161206776873590 |
0.578 |
|
| 2006 |
Sluis-Cremer N, Kempner ES. Radiation target analyses of DNA template/primer complexes. Biophysical Journal. 90: L61-3. PMID 16533846 DOI: 10.1529/Biophysj.106.083261 |
0.375 |
|
| 2006 |
Sluis-Cremer N, Ross T. Editorial: HIV-1 reverse transcriptase inhibitors: Drug resistance and drug development Current Pharmaceutical Design. 12: 1809-1810. DOI: 10.2174/138161206776873635 |
0.425 |
|
| 2005 |
Sluis-Cremer N, Arion D, Parikh U, Koontz D, Schinazi RF, Mellors JW, Parniak MA. The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. The Journal of Biological Chemistry. 280: 29047-52. PMID 15970587 DOI: 10.1074/Jbc.M503166200 |
0.587 |
|
| 2005 |
Radzio J, Sluis-Cremer N. Stereo-selectivity of HIV-1 reverse transcriptase toward isomers of thymidine-5'-O-1-thiotriphosphate. Protein Science : a Publication of the Protein Society. 14: 1929-33. PMID 15937285 DOI: 10.1110/Ps.051445605 |
0.791 |
|
| 2005 |
Tachedjian G, Radzio J, Sluis-Cremer N. Relationship between enzyme activity and dimeric structure of recombinant HTV-1 reverse transcriptase Proteins: Structure, Function and Genetics. 60: 5-13. PMID 15852304 DOI: 10.1002/Prot.20480 |
0.805 |
|
| 2005 |
Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. Febs Letters. 579: 379-84. PMID 15642347 DOI: 10.1016/J.Febslet.2004.11.099 |
0.596 |
|
| 2004 |
Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Current Hiv Research. 2: 323-32. PMID 15544453 DOI: 10.2174/1570162043351093 |
0.596 |
|
| 2004 |
Sluis-Cremer N, Arion D, Abram ME, Parniak MA. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. The International Journal of Biochemistry & Cell Biology. 36: 1836-47. PMID 15183348 DOI: 10.1016/J.Biocel.2004.02.020 |
0.53 |
|
| 2003 |
Sluis-Cremer N, Kempner E, Parniak MA. Structure-activity relationships in HIV-1 reverse transcriptase revealed by radiation target analysis. Protein Science : a Publication of the Protein Society. 12: 2081-6. PMID 12931006 DOI: 10.1110/Ps.03130503 |
0.518 |
|
| 2002 |
Sluis-Cremer N, Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. European Journal of Biochemistry / Febs. 269: 5103-11. PMID 12392542 DOI: 10.1046/J.1432-1033.2002.03216.X |
0.618 |
|
| 2002 |
Sluis-Cremer N, Arion D, Parniak MA. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Molecular Pharmacology. 62: 398-405. PMID 12130693 DOI: 10.1124/Mol.62.2.398 |
0.616 |
|
| 2002 |
Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. The Journal of Biological Chemistry. 277: 1370-4. PMID 11684697 DOI: 10.1074/jbc.M110254200 |
0.506 |
|
| 2000 |
Sluis-Cremer N, Arion D, Parniak MA. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) Cellular and Molecular Life Sciences. 57: 1408-1422. PMID 11078020 |
0.627 |
|
| 2000 |
Parniak MA, Sluis-Cremer N. Inhibitors of HIV-1 reverse transcriptase Advances in Pharmacology (San Diego, Calif.). 49: 67-109. PMID 11013761 |
0.541 |
|
| 2000 |
Sluis-Cremer N, Arion D, Kaushik N, Lim H, Parniak MA. Mutational analysis of Lys65 of HIV-1 reverse transcriptase Biochemical Journal. 348: 77-82. PMID 10794716 DOI: 10.1042/0264-6021:3480077 |
0.429 |
|
| 2000 |
Arion D, Sluis-Cremer N, Parniak MA. Mechanism by which phosphonoformic acid resistance mutations restore 3'- azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase Journal of Biological Chemistry. 275: 9251-9255. PMID 10734063 DOI: 10.1074/jbc.275.13.9251 |
0.463 |
|
| 2000 |
Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa MJ, Parniak MA. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-{spiro[4'-amino-2',2'-dioxo- 1',2'-oxathiole-5',3'- [2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]]}-3-ethylthymine Biochemistry. 39: 1427-1433. PMID 10684624 DOI: 10.1021/Bi991682+ |
0.459 |
|
| Show low-probability matches. |